U.S. Pharmaceuticals & Biotech Buy the Dip

Teva Pharmaceutical Industries

Market Cap: US$37.5b

Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.

Arrowhead Pharmaceuticals

Market Cap: US$10.4b

Develops medicines for the treatment of intractable diseases in the United States.

ImmunityBio

Market Cap: US$8.2b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

PTC Therapeutics

Market Cap: US$6.7b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

NewAmsterdam Pharma

Market Cap: US$3.9b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

IDEAYA Biosciences

Market Cap: US$3.4b

A precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Tarsus Pharmaceuticals

Market Cap: US$2.6b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Stoke Therapeutics

Market Cap: US$1.8b

Engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Iovance Biotherapeutics

Market Cap: US$1.8b

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Taysha Gene Therapies

Market Cap: US$1.7b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

MeiraGTx Holdings

Market Cap: US$1.1b

A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.

Solid Biosciences

Market Cap: US$956.9m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Annexon

Market Cap: US$922.4m

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Arbutus Biopharma

Market Cap: US$921.5m

A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

Immix Biopharma

Market Cap: US$748.9m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Ironwood Pharmaceuticals

Market Cap: US$693.0m

A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

Allogene Therapeutics

Market Cap: US$666.1m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

REGENXBIO

Market Cap: US$659.2m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

4D Molecular Therapeutics

Market Cap: US$590.7m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Kyverna Therapeutics

Market Cap: US$472.4m

A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

Prothena

Market Cap: US$462.3m

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.

Sutro Biopharma

Market Cap: US$461.3m

Operates as an oncology company.

Ovid Therapeutics

Market Cap: US$453.5m

A biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.

Cabaletta Bio

Market Cap: US$450.8m

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

Prelude Therapeutics

Market Cap: US$435.4m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Enanta Pharmaceuticals

Market Cap: US$396.6m

A biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.

Lyell Immunopharma

Market Cap: US$334.4m

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

Opus Genetics

Market Cap: US$314.6m

A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.

MacroGenics

Market Cap: US$286.0m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.

ALX Oncology Holdings

Market Cap: US$265.1m

A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

Coherus Oncology

Market Cap: US$226.7m

A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

Whitehawk Therapeutics

Market Cap: US$206.5m

A clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.

Nkarta

Market Cap: US$189.6m

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Canton Strategic Holdings

Market Cap: US$175.1m

Engages in the institutional blockchain adoption and digitization of financial markets in the United States.

Pyxis Oncology

Market Cap: US$154.6m

A clinical stage company, engages in the development of therapeutics to treat solid tumors.